CAMBRIDGE, Mass. (AP) _ Alnylam Pharmaceuticals Inc. (ALNY) on Thursday reported a loss of $163.6 million in its second quarter.

The Cambridge, Massachusetts-based company said it had a loss of $1.63 per share. Losses, adjusted for one-time gains and costs, came to $1.61 per share.

The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of $1.54 per share.

The RNA interference drug developer posted revenue of $29.9 million in the period, which beat Street forecasts. Five analysts surveyed by Zacks expected $19.9 million.

Alnylam shares have decreased 26 percent since the beginning of the year. The stock has risen 16 percent in the last 12 months.


This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on ALNY at